Basic and Diluted Net Income (Loss) per Share - Schedule of the Calculate Net Income (loss) Per Share (Detail) - USD ($)		3 Months Ended
		Mar. 31, 2022	Mar. 31, 2021
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Net income attributable to Thorne HealthTech, Inc.		$ 4,979,059	$ 4,706,490
Undistributed earnings attributable to Series E convertible preferred stockholders		0	(4,706,490)
Numerator for basic EPS- net income (loss) available to Thorne Health Tech, Inc. common stockholders (A)		4,979,059	0
Change in fair value of warrant liability		(65,919)	(1,627,751)
Undistributed earnings attributable to Series E convertible preferred stockholders, basic		0	4,706,490
Undistributed earnings attributable to Series E convertible preferred stockholders- diluted			(4,706,490)
Effect of dilutive securities		0	0
Numerator for diluted EPS-net income (loss) available to Thorne HealthTech, Inc. common stockholders (C)		$ 4,979,059	$ 0
Weighted average number of common shares outstanding – basic		52,564,779	17,650,035
Dilutive potential common shares	[1]	60,172	0
Denominator for diluted EPS-adjusted weighted average shares and assumed conversions		52,624,951	17,650,035
Basic EPS		$ 0.09	$ 0
Diluted EPS		$ 0.09	$ 0
Stock Option
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Dilutive potential common shares	[1]	60,172	0
Warrant [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Dilutive potential common shares	[1]	0	0
Restricted Stock Units (RSUs) [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Dilutive potential common shares	[1]	0	0

[1] Approximately 16.1 million warrants and stock-based awards were excluded from the computation of diluted EPS for the three months ended March 31, 2022, because the effect would have been anti-dilutive under the treasury stock method.